Back to search

University of Strathclyde

Real-world evaluation of utilisation patterns of lipid-lowering therapies (LLTs) and quality of lipid control in Kuwait : a national multi-study project

Abstract

dc:description.abstract

Introduction: Lipid-lowering therapies (LLTs), including statins and proproteinconvertase subtilisin/kexin type 9 inhibitors (PCSK9is), are used to manage elevatedlow-density lipoprotein cholesterol (LDL-C). Over time, LLT prescribing patterns havebeen shaped by evolving guidelines. However, national data on LLT utilisationpatterns and the quality of lipid control in Kuwait remain unknown.Methods: This thesis comprised three nationwide quantitative studies conductedacross healthcare settings governed by the Ministry of Health in Kuwait. First, aretrospective, repeated cross-sectional study utilising data from the Central MedicalStore (CMS) was conducted to quantify utilisation trends of LLTs over an 11-yearperiod (2012–2022). Second, a nationwide, cross-sectional design among patientsattending primary healthcare centres (PHCCs) was employed to evaluate LLTprescribing patterns and assess the extent of lipid control. Third, a retrospectivecohort study utilising routinely collected dispensing data from a tertiary cardiac carecentre was performed to evaluate the real-world effectiveness of PCSK9is between2016 and 2022. All data were analysed using descriptive statistics and regressionmethods, as appropriate.Results: At the national level, findings from the CMS data demonstrated a significantoverall increase in both utilisation and expenditure trends of LLTs. Utilisation,measured by number of supplied units per thousand inhabitants per year, rose by52% (n= 71,839), from 138,549 in 2012 to 210,388 in 2022, while defined daily dosesper thousand inhabitants per day increased by 119% (n= 62.2), from 52.4 in 2012 to114.6 in 2022. Statins accounted for the increase in utilisation. At the PHCC level,findings from the cross-sectional study showed that most patients were prescribedstatins (98.8%, n= 429/434). Lipid control was suboptimal, with only 20.4% (n=65/318) achieving LDL-C targets across all cardiovascular (CV) risk categories. At thetertiary care level, the real-world effectiveness study showed that PCSK9is significantly reduced LDL-C levels (n=104) by 41.9% (95% CI: -50.9% to -24.1%,p<0.001).Conclusion:The utilisation and expenditure of LLTsin Kuwait have increased substantially. Statinsremain the cornerstone of treatment, reflecting their continued role as first-linetherapy. Despite the widespread use of statins in PHCCs, lipid control remainssuboptimal, particularly among patients at extreme CV risk. PCSK9is reduced LDL-Csignificantly (~42%) but less than in clinical trials (~60%). These findings highlight theurgent need for targeted interventions to optimise lipid management.

Degree

thesis:*
Name dc:type.qualificationname
phd
Level dc:type.qualificationlevel
doctoral-pg
Grantor dc:publisher.institution
University of Strathclyde
Year dc:date.issued
2026

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Alsaffar, Noor Ahmad Jassim
Advisors dc:contributor.advisor
  • Kurdi, Amanj
  • Alowayesh, Maryam
  • Bennie, Marion
Author Identifier dc:creator.authoridentifier
  • 202187477

Rights

Identifiers

dc:identifier.*
Identifier
T17988

Chain of custody

source
Harvested from
University of Strathclyde
Base URL
stax.strath.ac.uk/catalog/oai
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Alsaffar, Noor Ahmad Jassim. Real-world evaluation of utilisation patterns of lipid-lowering therapies (LLTs) and quality of lipid control in Kuwait : a national multi-study project. doctoral-pg thesis, University of Strathclyde, 2026. https://stax.strath.ac.uk/concern/theses/hd76s0791